These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2097153)

  • 41. The value of estimating CA 125 in fluids from benign or malignant cysts, in the exudate and blood serum in women with ovarian cancer.
    Markowska J; Kopczyński Z; Szewierski Z; Markowski M; Niecewicz R
    Eur J Gynaecol Oncol; 1994; 15(1):29-32. PubMed ID: 8206067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Elevation of multiple serum markers in patients with stage I ovarian cancer.
    Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
    J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictive value of CA-125 levels in advanced ovarian cancer.
    Patsner B; Day TG
    Am J Obstet Gynecol; 1987 Feb; 156(2):440-1. PubMed ID: 3469916
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of serum CA-125 and lipid-associated sialic acid (LASA-P) in monitoring patients with invasive ovarian adenocarcinoma.
    Patsner B; Mann WJ; Vissicchio M; Loesch M
    Gynecol Oncol; 1988 May; 30(1):98-103. PubMed ID: 2452774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preoperative serum tumor-associated antigen levels in women with pelvic masses.
    Soper JT; Hunter VJ; Daly L; Tanner M; Creasman WT; Bast RC
    Obstet Gynecol; 1990 Feb; 75(2):249-54. PubMed ID: 2300353
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Meigs syndrome with elevated serum CA 125.
    Lin JY; Angel C; Sickel JZ
    Obstet Gynecol; 1992 Sep; 80(3 Pt 2):563-6. PubMed ID: 1495739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CA-125 values predictive of clinical response during second-line chemotherapy for epithelial ovarian cancer.
    Ng LW; Homesley HD; Barrett RJ; Welander CE; Case LD
    Am J Clin Oncol; 1989 Apr; 12(2):106-9. PubMed ID: 2705398
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CA 125 in monitoring chemotherapy of patients with ovarian cancer: early response to the treatment.
    Markowska J; Kopczyński Z; Manyś G; Szewierski Z
    Neoplasma; 1990; 37(6):687-92. PubMed ID: 2274087
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.
    Hunter VJ; Daly L; Helms M; Soper JT; Berchuck A; Clarke-Pearson DL; Bast RC
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1164-7. PubMed ID: 2171337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CA 125 in ovarian cancer.
    van der Burg ME; Lammes FB; Verweij J
    Neth J Med; 1992 Feb; 40(1-2):36-51. PubMed ID: 1579185
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The value of preoperative diagnosis before second-look laparotomy in ovarian cancer].
    Meden H; Rath W; Ohlmeyer D
    Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):101-5. PubMed ID: 2180783
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer.
    van der Burg ME; Lammes FB; Verweij J
    Ann Oncol; 1990 Jul; 1(4):301-2. PubMed ID: 2265140
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
    Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
    Gynecol Oncol; 1990 Sep; 38(3):373-6. PubMed ID: 2227551
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The value of CA 125 measurement before second-look laparotomy in patients with ovarian carcinoma.
    Hørding U; Toftager-Larsen K; Lund B; Dreisler A; Daugaard S; Lundvall F; Knudsen JB; Bock JE
    Eur J Gynaecol Oncol; 1994; 15(3):217-21. PubMed ID: 7957327
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Resection guided by antibodies (REGAJ): a diagnostic procedure during second-look operation in ovarian cancer patients.
    Jäger W; Feistel H; Paterok EM; Ronay G; Tulusan AH; Wolf F; Lang N
    Br J Cancer Suppl; 1990 Jul; 10():18-20. PubMed ID: 2383476
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy.
    Makar AP; Kristensen GB; Børmer OP; Tropé CG
    Gynecol Oncol; 1993 Apr; 49(1):73-9. PubMed ID: 8482563
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer.
    Berek JS; Chung C; Kaldi K; Watson JM; Knox RM; Martínez-Maza O
    Am J Obstet Gynecol; 1991 Apr; 164(4):1038-42; discussion 1042-3. PubMed ID: 2014824
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A study of the monoclonal antibody OC 125 to diagnose malignant ovarian tumors.
    Li XG; Chen DX; Schwartz PE; Yang Z
    Gynecol Oncol; 1989 Mar; 32(3):327-30. PubMed ID: 2920953
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assays.
    Ward BG; McGuckin MA; Ramm LE; Coglan M; Sanderson B; Tripcony L; Free KE
    Cancer; 1993 Jan; 71(2):430-8. PubMed ID: 8422635
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of beta1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer.
    Odunsi K; Ghamande S; Chandrasekaran EV; Ta A; Moysich KB; Driscoll D; Matta K; Lele S
    Am J Obstet Gynecol; 2002 Sep; 187(3):575-80. PubMed ID: 12237630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.